Moderna loses challenge to Arbutus patent on vaccine technology
ALEXANDRIA, Virginia: Shares of Moderna fell nearly 10 per cent after it lost a bid to invalidate a US patent owned by Arbutus Biopharma that poses a potential obstacle to Moderna's efforts to develop next-generation vaccines, including a COVID-19 vaccine.
An administrative court run by the US Patent and Trademark Office rejected arguments by Moderna that an Arbutus patent known as the '069 patent should be revoked because it described obvious concepts.
The '069 patent relates to lipid nanoparticle (LNP) technology that allows the human body to make its own therapeutic proteins.
LNP technology is crucial to Moderna's vaccine development efforts, and the patent ruling could increase pressure on the Cambridge, Massachusetts-based firm to pay for a license to Arbutus' patent portfolio,...









